Am. J. Respir. Crit. Care Med., Volume 158, Number 5, November 1998, 1432-1441

Procollagen Types I and III Aminoterminal Propeptide Levels during Acute Respiratory Distress Syndrome and in Response to Methylprednisolone Treatment

G. UMBERTO MEDURI, ELIZABETH A. TOLLEY, ALBERT CHINN, FRANKIE STENTZ, and ARNOLD POSTLETHWAITE

Departments of Medicine and Preventive Medicine, and Memphis Lung Research Program, University of Tennessee, Baptist Memorial Hospitals, and Veterans Affairs Medical Center, Memphis, Tennessee

Ineffective lung repair in patients with unresolving acute respiratory distress syndrome (ARDS) is accompanied by progressive fibroproliferation, inability to improve lung injury score (LIS), progressive multiple organ dysfunction syndrome (MODS), and an unfavorable outcome. Our aim was to investigate the relationship between fibrogenesis, pulmonary and extrapulmonary organ dysfunction, and outcome during the natural course of ARDS and in response to prolonged methylprednisolone treatment. We investigated 29 patients with ARDS. We obtained serial measurements of plasma and BAL procollagen aminoterminal propeptide type I (PINP) and type III (PIIINP) levels and components of the lung injury score (LIS) and MODS score. A reduction in LIS greater than one point from day 1 to day 7 of ARDS divided patients in improvers (group 1, n = 7) and nonimprovers (n = 22). Nonimprovers included those who were recruited (day 9 ± 3 of ARDS) into a prospective, randomized, double-blind, placebo-controlled trial investigating prolonged methylprednisolone therapy in unresolving ARDS (group 2, n = 17), and those who died (all by day 10 of ARDS) prior to meeting eligibility criteria for the randomized trial (group 3, n = 5). On day 1 of ARDS, plasma PINP or PIIINP levels were elevated in all patients. By day 7 of ARDS, mean plasma PINP or PIIINP levels were unchanged in group 1 but increased significantly in group 2 (p = 0.0002) and group 3 (p = 0.03). On day 7, patients with plasma PINP levels less than 100 ng/ml were 2.5 times more likely to survive (95% CI: 0.855-7.314), and patients with plasma PIIINP levels greater than 25 ng/ml were nine times more likely to die (95% CI: 1.418-55.556). In group 2, patients taking placebo (n = 6) had no change in plasma PINP or PIIINP levels over time, while patients treated with methylprednisolone (n = 11) had a rapid and sustained reduction in mean plasma and bronchoalveolar lavage (BAL) PINP and PIIINP levels. By day 3 of treatment, mean plasma PINP and PIIINP levels (ng/ml) decreased from 100 ± 9 to 45 ± 8 (p = 0.0001) and 31 ± 3 to 12 ± 3 (p = 0.0008), respectively. After 8 to 15 d of methylprednisolone, mean BAL PINP and PIIINP levels (ng/ml) decreased from 63 ± 25 to 6 ± 23 (p = 0.002) and 42 ± 5 to 10 ± 3 (p = 0.003), respectively. Estimated partial correlation coefficients indicated that as plasma PINP and PIIINP levels decreased over the first 7 d of methylprednisolone treatment, positive end-expiratory pressure, creatinine, bilirubin, and temperature also decreased, while Pa_O2:FI_O2 increased. In early ARDS, plasma PINP and PIIINP levels are elevated and continue to increase over time in those not improving. Among nonimprovers, those randomized to prolonged methylprednisolone treatment had a rapid and significant reduction in plasma and BAL aminoterminal propeptide levels and similar changes in lung injury and MODS scores. These findings provide additional evidence of an association between biological efficacy and physiologic response during prolonged methylprednisolone treatment of unresolving ARDS.

This article has been cited by other articles:

				N. R. Webster and H. F. Galley Immunomodulation in the critically ill Br. J. Anaesth., July 1, 2009; 103(1): 70 - 81. [Abstract] [Full Text] [PDF]

				J. E. Levitt, M. K. Gould, L. B. Ware, and M. A. Matthay Analytic Review: The Pathogenetic and Prognostic Value of Biologic Markers in Acute Lung Injury J Intensive Care Med, May 1, 2009; 24(3): 151 - 167. [Abstract] [PDF]

				D. E. McClintock, B. Starcher, M. D. Eisner, B. T. Thompson, D. L. Hayden, G. D. Church, M. A. Matthay, and the National Heart, Lung, Blood Institute Acute Re Higher urine desmosine levels are associated with mortality in patients with acute lung injury Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L566 - L571. [Abstract] [Full Text] [PDF]

				A. Dovio, L. Perazzolo, G. Osella, M. Ventura, A. Termine, E. Milano, A. Bertolotto, and A. Angeli Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4923 - 4928. [Abstract] [Full Text] [PDF]

				P. R. M. Rocco, A. B. Souza, D. S. Faffe, C. P. Passaro, F. B. Santos, E. M. Negri, J. G. M. Lima, R. S. Contador, V. L. Capelozzi, and W. A. Zin Effect of Corticosteroid on Lung Parenchyma Remodeling at an Early Phase of Acute Lung Injury Am. J. Respir. Crit. Care Med., September 15, 2003; 168(6): 677 - 684. [Abstract] [Full Text] [PDF]

				W A Dik, R J McAnulty, M A Versnel, B A E Naber, L J I Zimmermann, G J Laurent, and S E Mutsaers Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats Thorax, September 1, 2003; 58(9): 765 - 771. [Abstract] [Full Text] [PDF]

				G.U. Meduri, P. Carratu, and A.X. Freire Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS Eur. Respir. J., August 1, 2003; 22(42_suppl): 57s - 64s. [Abstract] [Full Text] [PDF]

				M. P. Keane, S. C. Donnelly, J. A. Belperio, R. B. Goodman, M. Dy, M. D. Burdick, M. C. Fishbein, and R. M. Strieter Imbalance in the Expression of CXC Chemokines Correlates with Bronchoalveolar Lavage Fluid Angiogenic Activity and Procollagen Levels in Acute Respiratory Distress Syndrome J. Immunol., December 1, 2002; 169(11): 6515 - 6521. [Abstract] [Full Text] [PDF]

				P. R. M. ROCCO, E. M. NEGRI, P. M. KURTZ, F. P. VASCONCELLOS, G. H. SILVA, V. L. CAPELOZZI, P. V. ROMERO, and W. A. ZIN Lung Tissue Mechanics and Extracellular Matrix Remodeling in Acute Lung Injury Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1067 - 1071. [Abstract] [Full Text] [PDF]

				R. P. MARSHALL, G. BELLINGAN, S. WEBB, A. PUDDICOMBE, N. GOLDSACK, R. J. MCANULTY, and G. J. LAURENT Fibroproliferation Occurs Early in the Acute Respiratory Distress Syndrome and Impacts on Outcome Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1783 - 1788. [Abstract] [Full Text]

				T. G. Janz, R. Madan, J. J. Marini, W. R. Summer, G. U. Meduri, R. M. Smith, G. R. Epler, and J. Schnader Clinical Conference on Management Dilemmas: Progressive Infiltrates and Respiratory Failure Chest, February 1, 2000; 117(2): 562 - 572. [Full Text] [PDF]

				M. A. JANTZ and S. A. SAHN Corticosteroids in Acute Respiratory Failure Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100. [Full Text]

				V. M. Ranieri, P. M. Suter, C. Tortorella, R. De Tullio, J. M. Dayer, A. Brienza, F. Bruno, and A. S. Slutsky Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome: A Randomized Controlled Trial JAMA, July 7, 1999; 282(1): 54 - 61. [Abstract] [Full Text] [PDF]

				G. U. Meduri Levels of Evidence for the Pharmacologic Effectiveness of Prolonged Methylprednisolone Treatment in Unresolving ARDS Chest, July 1, 1999; 116 (2009): 116S - 118S. [Full Text]

				A. Wheeler, G. R. Bernard, D. Schoenfeld, K. Steinberg, E. A. Tolley, G. U. Meduri, A. S. Headley, E. Golden, S. J. Carson, and R. A. Umberger Methylprednisolone for Unresolving ARDS JAMA, December 23, 1998; 280(24): 2074 - 2074. [Full Text] [PDF]